Safety, Immune and Tumor Response to a Multi-component Immun

[lakers]

clinicaltrials.gov/ct2/show/NCT01026051?term=Mannkind&rank=8
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Vaccine Therapy in Treating Patients With Stage IV Melanoma
clinicaltrials.gov/ct2/show/NCT00033228?term=Mannkind&rank=20

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
clinicaltrials.gov/ct2/show/NCT00423254?term=Mannkind+cancer&rank=2

Conditions: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME

clinicaltrials.gov/ct2/show/NCT00688090?term=Mannkind+cancer&rank=5
5 Completed Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
Conditions: Advanced Melanoma; Stage III and IV Melanoma
Interventions: Biological: Biological: MKC1106-MT; Biological: Biological: MKCC1106-MT